Oncologists and patients are celebrating this new FDA decision
Industry Buzz
A 71% response rate is unprecedented in this cancer subtype, and not only is the data strong in showing that this treatment works, but zongertinib has the added convenience of being a once-daily oral therapy.
—John Heymach, MD, oncologist
This is a landmark moment for the HER-2-positive lung cancer community. It's such encouraging news for patients and their families. Deep appreciation to all who kept pushing forward to make this promise into progress.
—The LUNGevity Foundation
On August 8, 2025, the FDA made a landmark decision that could shift the treatment landscape for patients with HER2-positive non-small cell lung cancer (NSCLC).
The approval of zongertinib, an oral pill, marks the first time an oral HER2-targeted therapy has been approved for advanced lung cancer.
This significant step brings new hope to patients and provides oncologists with a much-needed option to treat this aggressive form of cancer.
The significance for doctors and patients
HER2 mutations are found in about 2–5% of NSCLC cases, and until now, treatment options for these patients were limited. []
Zongertinib’s approval offers a novel solution for those with advanced, non-squamous NSCLC who have already undergone chemotherapy. As a targeted therapy, zongertinib specifically inhibits the HER2 receptor, which plays a crucial role in cancer cell growth.
The oral formulation makes it a practical, convenient option for patients who may struggle with traditional intravenous treatments.
Oncologists are particularly excited about the drug’s potential to improve patient outcomes, especially since the treatment is now available for patients who have already tried chemotherapy.
In the Beamion LUNG-1 trial, which led to this approval, the results were promising: Among 75 patients who had chemotherapy but no prior HER2-targeted treatment, 71% saw tumor shrinkage. []
“A 71% response rate is unprecedented in this cancer subtype, and not only is the data strong in showing that this treatment works, but zongertinib has the added convenience of being a once-daily oral therapy,” lead study author John Heymach, MD, said. []
Related: You need to take a closer look at this targeted therapy for lung cancerReactions among the medical community
Oncologist Eric K. Singhi, MD, shared his excitement on social media, emphasizing the long-awaited approval of zongertinib. His Instagram post captured the collective sentiment in the oncology community: "Finally!! The #FOMO for our patients with HER2-positive NSCLC is over!!!"
The official Instagram account of the Oncogene Cancer Research commented on Dr. Singhi's post: "A huge step forward for people with HER2-positive lung cancer. This approval brings real hope—and a much-needed targeted option—for those who have been waiting far too long. Grateful to the researchers, clinicians, trial participants, and advocates who made this milestone possible."
The LUNGevity Foundation echoed similar sentiments: "This is a landmark moment for the HER-2-positive lung cancer community. It's such encouraging news for patients and their families. Deep appreciation to all who kept pushing forward to make this promise into progress."
This enthusiasm reflects a pivotal moment in cancer treatment. The approval of zongertinib not only fills a crucial gap but also underscores the importance of targeted therapies in modern oncology.
With this new treatment, doctors now have an oral option that has shown effective results in patients who may have been running out of choices.
What’s next?
While this approval is groundbreaking, oncologists will need to monitor patient responses carefully. As with all cancer treatments, individual responses can vary, and ongoing research and real-world data will be critical in further understanding how zongertinib fits into the broader treatment landscape for HER2-positive NSCLC.
For now, however, this approval marks a moment of celebration in the oncology community—a long-awaited step forward for patients and doctors alike.
Related: Adding this one thing pre-surgery could save more lung cancer patients